INSULIN RESISTANCE IN DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS PATIENTS DURING THE FIRST MONTH OF ANTITUBERCULAR TREATMENT

Olga Mykolaivna Shvets; Olga Stanislavna Shevchenko; Hanna Leonidivna Stepanenko

doi:10.31435/rsglobal_wos/31082019/6650

Olga Mykolaivna Shvets PhD-student, Ukraine, Kharkiv, Kharkiv National Medical University, Department of Phthisiology and Pulmonology
Olga Stanislavna Shevchenko MD, Professor, Ukraine, Kharkiv, Kharkiv National Medical University, Department of Phthisiology and Pulmonology
Hanna Leonidivna Stepanenko PhD, Ukraine, Kharkiv, Kharkiv National Medical University, Department of Phthisiology and Pulmonology

DOI: https://doi.org/10.31435/rsglobal_wos/31082019/6650

Keywords: insulin resistance, antitubercular treatment, liver function, drug- susceptible tuberculosis

Abstract

The study was aimed to investigate insulin resistance development in drug-susceptible newly diagnosed pulmonary tuberculosis patients. Those patients who developed insulin resistance during the 30 days of antitubercular therapy have expressed metabolic changes, that may be associated with impaired liver function due to the toxic effects of antitubercular drugs.

References

Yorke E, Atiase Y, Akpalu J, Sarfo-Kantanka O, Boima V, Dey ID. The Bidirectional Relationship between Tuberculosis and Diabetes. Tuberc Res Treat. 2017;2017:1702578. doi: 10.1155/2017/1702578

Philips L, Visser J, Nel D, Blaauw R. The association between tuberculosis and the development of insulin resistance in adults with pulmonary tuberculosis in the Western sub-district of the Cape Metropole region, South Africa: a combined cross-sectional, cohort study. BMC Infect Dis. 2017;17(1):570. Published 2017 Aug 15. doi: 10.1186/s12879-017-2657-5

Bershtejn, A.M., & Kovalenko, I.G. (2010). “Metabolicheski zdorovye” litsa s ozhireniyem i metabolicheskie priznaki ozhireniya u lits s normalnoy massoy tela: chto za etim stoit? [Metabolically healthy obese subjects and metabolic signs of obesity in subjects with normal body weight: what is behind?] Problemy endokrinologii – Problems of Endocrinology, 3, 47-51 [in Russian].

R.M. Yasinskyi. Insulin resistance in patients with newly diagnosed pulmonary tuberculosis with different treatment outcome. Infectious Diseases. 2018; (4): 10-4

Pickup JC. Inflammation and activated innate immunity in the pathogensis of type 2 diabetes. Diabetes Care. 2004;27(3):813–23

Olga S.Shevchenko, Lilia D. Todoriko, Iryna A. Ovcharenko, Yevheniia B. Radzishevska, Olga M. Shvets, Sergiy S. Ovcharenko, Igor O. Semianiv, Volodymyr V. Vivsyannuk. Dynamics of aldosterone, connective tissue reorganization and glucose level as markers for tuberculosis treatment effectiveness. J Archives of the Balkan Medical Union. Vol. 54, Nr. 2, June, 2019. doi: 10.31688/ABMU.2019.54.2.08

Illuri VD, Layden BT, Aleppo G. Extreme Insulin Resistance in Critically Ill Patient With Sepsis. Clin Diabetes. 2016; 34(3):158–160. doi:10.2337/diaclin.34.3.158

Erol A. Visceral adipose tissue specific persistence of Mycobacterium tuberculosis may be reason for the metabolic syndrome. Med Hypotheses. 2008 Aug;71(2):222-8. doi: 10.1016/j.mehy.2008.03.028.

Boillat-Blanco N, Ramaiya KL, Mganga M, Minja LT, Bovet P, Schindler C, Von Eckardstein A, Gagneux S, Daubenberger C, Reither K, Probst-Hensch N. Transient Hyperglycemia in Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms. J Infect Dis. 2016 Apr 1; 213(7):1163-72. doi: 10.1093/infdis/jiv568.

Hu YH, Kuo SW, Wu DA. Relationships between hemoglobin and each component of metabolic syndrome: a special focus on elderly without medication. Int J Gerontol. 2016;10:22-27

Aoki I, Taniyana M, Toyama K, Homori M, Ishikawa K. Stimulatory effect of human insulin in erythroid progenitors (CFU-E and BFU-E) in human CD34 separated bone marrow cells and the relationship between insulin and erythropoetin. Stem Cells 1984;12:329-38.

McCarty MF. Hyperinsulinemia may boost both hematocrit and iron absorption by up-regulating activity of hypoxia-inducible factor-1alpha. Med Hypotheses 2003;61:567-73.

Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci. 2003 Jan 1;8:d464-76.